Key Takeaway
If your doctor has mentioned dulaglutide, you aren't alone. This dulaglutide Trulicity guide covers one of the most widely prescribed GLP-1 medications for type 2 diabetes management.
If your doctor has mentioned dulaglutide, you aren't alone. This dulaglutide Trulicity guide covers one of the most widely prescribed GLP-1 medications for type 2 diabetes management. While it doesn't produce the dramatic weight loss numbers of newer options like semaglutide or tirzepatide, dulaglutide has carved out a solid role in diabetes care. It's effective, well-tolerated, and often has better insurance coverage than some alternatives.
Key Takeaways: - Learn how dulaglutide works - Blood Sugar Control and Weight Loss - Insurance Coverage and Cost - Who Is Dulaglutide Best For
Here is what you need to know.
How Dulaglutide Works
Dulaglutide is a GLP-1 receptor agonist given as a weekly subcutaneous injection. Like other medications in this class, it mimics the GLP-1 hormone your body naturally produces after eating.
It works through three main mechanisms. First, it improves insulin secretion when your blood sugar is improved. This happens in a glucose-dependent manner, meaning it doesn't push your blood sugar dangerously low on its own. Second, it reduces glucagon secretion, which prevents your liver from dumping excess sugar into your bloodstream. Third, it slows gastric emptying, helping you feel full longer after meals.
"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.") Dr. Caroline Apovian, MD, Harvard Medical School
The available doses are 0.75 mg and 1.5 mg, with higher doses of 3.0 mg and 4.5 mg also approved for additional blood sugar control. The medication comes in a pre-filled, single-use pen that doesn't require you to see the needle, which many patients find less intimidating than other injection devices.
Dulaglutide was FDA-approved in 2014 for type 2 diabetes. It isn't specifically approved for weight management as a standalone indication, though weight loss is a common benefit.
For a comparison with other GLP-1 options, see our .
Blood Sugar Control and Weight Loss
For blood sugar management, dulaglutide performs well. Clinical trials showed A1C reductions of 1.0-1.5% depending on the dose, which is meaningful for diabetes control.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Free Download: GLP-1 Medication Comparison One-Pager Compare dulaglutide against semaglutide, tirzepatide, and every other GLP-1 in one easy chart. Get yours free (we'll email it to you instantly. [Email Input] [Download Button]
Weight loss with dulaglutide is more modest than with semaglutide or tirzepatide. In clinical trials, participants lost about 3-5% of their body weight on dulaglutide, compared to about 15% with semaglutide and about 22% with tirzepatide.
But for people whose primary concern is blood sugar control rather than weight loss, dulaglutide is a solid choice. The A1C improvements are clinically significant and help reduce the risk of diabetes complications like nerve damage, kidney disease, and eye problems.
The REWIND trial (Gerstein et al., Lancet, 2019) also showed cardiovascular benefits. Dulaglutide reduced major adverse cardiovascular events by 12% in people with type 2 diabetes. This makes it one of several GLP-1 medications with proven heart protection.
Insurance Coverage and Cost
One practical advantage of dulaglutide is insurance coverage. Because it has been on the market since 2014 and has strong diabetes data, many insurance plans include it on their formulary. Some plans prefer dulaglutide over newer, more expensive alternatives.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Without insurance, dulaglutide costs over $900 per month at retail pricing. With insurance, copays can be much lower. Manufacturer savings programs are also available for eligible patients.
If weight management is your primary goal rather than just blood sugar control, you may want to discuss compounded semaglutide through FormBlends. Compounded semaglutide offers stronger weight loss results and may cost less than brand-name options. Visit our for details.
For a cost comparison across GLP-1 options, check our .
Who Is Dulaglutide Best For?
Dulaglutide fits best for people who need a well-established diabetes medication with good insurance coverage. If your primary concern is A1C control and your insurance covers dulaglutide favorably, it's a reasonable choice.
It may also suit people who prefer the hidden-needle pen design. The Trulicity pen is designed so you never see the needle, which reduces anxiety for people who are uncomfortable with injections.
If your goals include significant weight loss alongside blood sugar management, semaglutide or tirzepatide may be better options. These newer medications produce substantially more weight loss while also improving blood sugar control.
Your provider can help you weigh the pros and cons based on your health history, insurance coverage, and personal priorities. For more on the market of options, see our .
Frequently Asked Questions
How is dulaglutide different from semaglutide?
Both are weekly GLP-1 injections. Semaglutide produces more weight loss (about 15% vs. 3-5%) and has slightly stronger A1C reduction. Dulaglutide may have better insurance coverage and uses a hidden-needle pen design. Your provider can help determine which is right for your goals.
What are the side effects of dulaglutide?
Common side effects include nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. These are typically mild and improve over time. For detailed management strategies, read our .
Can I use dulaglutide for weight loss only?
Dulaglutide is FDA-approved for type 2 diabetes, not as a standalone weight management medication. While it does cause weight loss, the amount is less than what semaglutide or tirzepatide offer. If weight loss is your primary goal, discuss other options with your provider.
Does dulaglutide protect the heart?
Yes. The REWIND trial showed dulaglutide reduced major cardiovascular events by 12% in people with type 2 diabetes. This benefit adds to the case for using GLP-1 medications in people with diabetes and cardiovascular risk factors.
What's Your Next Move?
You have the information. Now let a licensed provider help you put it into action. FormBlends makes it simple, answer a few questions and get a personalized recommendation.
Medical References
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2[4] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3[5] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4[6] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
This article is for educational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →